As of 11:06am ET
| -0.025 / -0.36%|
The 3 analysts offering 12-month price forecasts for Melinta Therapeutics, Inc. have a median target of 15.00, with a high estimate of 21.00 and a low estimate of 10.00. The median estimate represents a +116.61% increase from the last price of 6.93.
The current consensus among 4 polled investment analysts is to Hold stock in Melinta Therapeutics, Inc.. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.